Welcome to our dedicated page for Dogwood Therapeutics news (Ticker: DWTX), a resource for investors and traders seeking the latest updates and insights on Dogwood Therapeutics stock.
Dogwood Therapeutics develops new medicines for pain and neuropathic disorders as a development-stage biopharmaceutical company listed on Nasdaq under DWTX. Company news centers on its pain and neuropathy pipeline, including Halneuron®, a non-opioid NaV 1.7 analgesic in development for chemotherapy-induced neuropathic pain, and SP16 IV, an LRP1 agonist program for chemotherapy-related pain and neuropathy.
Recurring updates also cover clinical and regulatory developments, FDA designations and investigational-drug activity, intellectual-property work tied to synthetic Halneuron®, financial results, financing activity, shareholder communications, and licensing arrangements involving anti-viral assets such as IMC-1 and IMC-2.
Dogwood Therapeutics (Nasdaq: DWTX) will host a virtual key opinion leader event on September 1, 2026 at 10:00 AM ET to discuss Halneuron® for treating chemotherapy induced neuropathic pain (CINP). Expert speakers and management will cover the NaV 1.7 pain-signaling mechanism, Halneuron’s selective non-opioid profile, and prior pre-clinical and clinical data.
According to Dogwood Therapeutics, the event will also review positive interim results from the ongoing randomized Phase 2b CINP trial (HAL-CINP; NCT06848348), where 210–240 U.S. patients receive 8 subcutaneous doses over 14 days, and will discuss synthetic Tetrodotoxin manufacturing to support planned Phase 3 development.
Dogwood Therapeutics (Nasdaq: DWTX) reported second quarter 2026 results and clinical progress. The Phase 2b Halneuron® trial in chemotherapy‑induced neuropathic pain has enrolled 217 patients, with top‑line data expected in fall 2026, and a 12‑week open‑label extension study has begun. SP16 IV received FDA IND clearance, with a Phase 1b CIPPN trial to start in second‑half 2026, fully funded by the National Cancer Institute.
Dogwood reported Q2 2026 research and development expenses of $3.2 million and general and administrative expenses of $1.6 million. A non‑cash IPR&D impairment of $9.2 million, partly offset by a $2.5 million deferred tax benefit, led to a net loss of $11.5 million. Cash of $9.6 million is expected to fund operations through the Phase 2b readout in Q4 2026. The company also highlighted a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million and noted payments could benefit holders of its October 2024 CVRs.
Dogwood Therapeutics (Nasdaq: DWTX) reported enrollment of the first 200 patients in its ongoing HAL-CINP Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain. According to the company, the early termination rate among these patients is 4.5%, suggesting Halneuron and placebo have been well tolerated so far.
An independent statistical review committee previously examined unblinded data and concluded Halneuron-treated patients showed separation from placebo in pain improvement over four weeks. HAL-CINP is a randomized trial in approximately 210–240 patients at about 25 U.S. sites, using 8 subcutaneous doses over 14 days and 28 days of follow-up. The primary endpoint is change from baseline to week four in average daily 24-hour recall pain intensity scores, with top-line data expected in fall 2026.
Dogwood Therapeutics (Nasdaq:DWTX) appointed biopharma executive and OrbiMed venture partner Iain Dukes, Ph.D., as Chair of its newly formed Scientific Advisory Board. He will advise on Dogwood’s pipeline, including Halneuron in chemotherapy-induced neuropathic pain with Phase 2b data projected for fall 2026, and SP16, cleared by the FDA for Phase 1b in chemotherapy-induced peripheral neuropathy.
Dogwood Therapeutics (NASDAQ:DWTX) began a 12-week open-label Phase 2b extension study of Halneuron for chemotherapy induced neuropathic pain (CINP). The trial follows a positive interim assessment of a 4-week double-blind study and will collect additional safety and efficacy data.
Interim analysis based on 97 patients supported continuing the Phase 2b trial with a 210–240 patient sample to achieve 80% power. Top-line Phase 2b results are expected in fall 2026, with a Phase 3 program projected to start in the first half of 2027.
Dogwood Therapeutics (Nasdaq:DWTX) reported Q1 2026 results and pipeline progress. The Halneuron® Phase 2b CINP trial has enrolled 164 patients, with top-line data expected in fall 2026. SP16 received FDA IND clearance for a fully NCI-funded Phase 1b CIPPN trial.
The company announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100M. Q1 2026 R&D expenses were $2.7M and G&A $2.4M. Net loss was $5.0M ($0.15/share). Cash of $13.2M is expected to fund operations into Q4 2026.
Dogwood Therapeutics (Nasdaq: DWTX) will report its first quarter 2026 financial results on Thursday, May 14, 2026, before the open of the financial markets. Investors can expect a standard quarterly release and any accompanying investor materials or conference information to be shared around that time.
Dogwood Therapeutics (NASDAQ: DWTX) entered a global development and commercialization partnership with PRIDCor for antiviral candidates IMC-1 and IMC-2 dated April 23, 2026. PRIDCor will finance development; Dogwood is entitled to a tiered royalty up to 15%, 9% of future PRIDCor capital for these assets, and potential payments capped at $100 million. Dogwood will focus internally on Halneuron and SP16. Payments that qualify as CVR-related will be passed to CVR holders as required.
Dogwood Therapeutics (NASDAQ: DWTX) announced FDA acceptance of an IND for SP16, an IV candidate to treat chemotherapy-induced pain and peripheral neuropathy (CIPPN). Serpin Pharma is regulatory sponsor; a $2.5 million NCI grant will fully fund the planned Phase 1b trial, with enrollment expected mid-2026.
Dogwood holds a royalty-free global license to Serpin’s IV SP16 formulation acquired in September 2025.
Dogwood Therapeutics (Nasdaq: DWTX) reported Q4 and full-year 2025 results and clinical updates. Key items: interim Phase 2b analysis showed Halneuron® separating from placebo in a 97-patient subset; 143 patients recruited; trial >50% enrolled with top-line data expected in Q3 2026. The company completed a financing of up to $26.9M, receiving $12.5M gross and $11.4M net in Jan 2026, and had $6.5M cash at Dec 31, 2025, expected to fund operations into Q4 2026.
Full-year R&D rose to $21.8M vs $3.5M in 2024; net loss was $35.5M or $7.13 per share.